Fusion Pharmaceuticals was acquired by AstraZeneca for up to USD 2.4 billion.
Fusion Pharmaceuticals is a biopharmaceutical company focused on developing targeted alpha-particle radiotherapeutics for treating cancer, utilizing proprietary technologies to link medical isotopes to targeting molecules
Fusion Pharmaceuticals is a biopharmaceutical company focused on developing targeted alpha-particle radiotherapeutics for treating cancer, utilizing proprietary technologies to link medical isotopes to targeting molecules.